EUVIMEDEUVIMED entdecken
Crossref

Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile

Tianbing Wang, Kai Guo, Di Zhang, Haibo Wang, Jimin Yin, Haodong Cui, Wenyong Wu

International Immunopharmacology · 2023-07 · 120 · 110368

DOI: 10.1016/j.intimp.2023.110368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023-07. Verfasst von Tianbing Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Anhui No.2 Provincial People's Hospital, Hefei 230000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Anhui Science and Technology Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new mode of cell death, disulfidptosis, has been discovered. Clinical prognostic significance of disulfidptosis related pattern in hepatocellular carcinoma(HCC). In this study, a risk score model was established based on disulfidptosis model to analyze the role of risk score in clinical prognosis, immune cell infiltration, drug sensitivity and immunotherapy response. Disulfidptosis subtype were constructed based on the transcriptional profiles of 15 disulfidptosis-related genes(DRGs). All 601 samples were defined as high risk group(HRG) and low risk group(LRG) based on the disulfidptosis risk score. Drug sensitivity and response to immunotherapy were calculated by immunophenotypic score(IPS), tumor prediction, tumor immune dysfunction and rejection(TIDE). RT-qPCR was used to determine the mRNA level of disulfidptosis prognostic gene. Risk groups was identified as potential predictors of immune cell infiltration, drug sensitivity, and immunotherapy responsiveness. HRG may benefit from immunotherapy. Classification is very effective in predicting the prognosis and therapeutic effect of patients, and provides a reference for accurate individualized treatment. This study suggests that new biomarkers related to Disulfidptosis can be used in clinical diagnosis of liver cancer to predict prognosis and treatment targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansPrognosisImmunotherapyCell DeathTumor MicroenvironmentBiomarkers, Tumor

Stichwörter der Autor:innen

DisulfidptosisDrug sensitivityHepatocellular carcinomaImmune cell infiltrationImmunotherapy responsePrognosis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of General Surgery, Anhui No.2 Provincial People's Hospital, Hefei 230000, China
  • Anhui Medical University, Hefei 230000, China
  • Anhui No.2 Provincial People's Hospital affiliated to Anhui Medical University, Hefei 230000, China
  • The Fifth Clinical Medical College of Anhui Medical University, Hefei 230000, China
  • Department of General Surgery, First affiliated Hospital of Anhui Medical University, Hefei 230000, China

Förderung

  • Anhui Science and Technology Department

Zitieren

APA

Wang, T., Guo, K., Zhang, D., Wang, H., Yin, J., Cui, H., & Wu, W. (2023). Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. International Immunopharmacology, 120, 110368. https://doi.org/10.1016/j.intimp.2023.110368

Vancouver

Wang T, Guo K, Zhang D, Wang H, Yin J, Cui H, et al. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. International Immunopharmacology. 2023;120:110368. doi:10.1016/j.intimp.2023.110368

BibTeX
@article{Wang2023,
  author = {Wang, Tianbing and Guo, Kai and Zhang, Di and Wang, Haibo and Yin, Jimin and Cui, Haodong and Wu, Wenyong},
  title = {Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {120},
  pages = {110368},
  doi = {10.1016/j.intimp.2023.110368}
}
Kostenlos starten →